Stroke: Dr. Thomas Devlin on Robotic TCD, Stroke Workflows, & Detecting Missed PFOs

Why are so many strokes in young patients missed? Dr. Thomas Devlin, nationally recognized stroke neurologist and executive medical director at CHI Memorial, explains how robotic transcranial Doppler (TCD) is reshaping stroke and PFO pathways.We cover why TCD is more sensitive than traditional echo, what the Bubble Trial revealed, and how robotic automation is changing workflows in neurology and cardiology.Episode Breakdown 00:00 – Opening and the challenge of detecting PFO with echo 01:11 – Introducing Dr. Thomas Devlin and the Bubble Trial 03:01 – Why strokes in young patients often go unexplained 05:25 – EEG vs robotic TCD: sensitivity and workflow 07:09 – Why PFO must always stay on the differential 10:13 – Meta-analyses and limitations of echo sensitivity 12:29 – Advantages of robotic TCD and real-world performance 15:46 – Benefits for techs and labs: automation and ease of use 16:06 – The Bubble Trial: robotic TCD detects 3x more large shunts 18:02 – Case study: negative echo, positive robotic TCD, large PFO 19:41 – Editorial response and the call for independent validation 20:16 – The Bubble-QE study: real-world validation and outcomes 22:53 – Multicenter results: robotic TCD vs echo and TEE 24:11 – Integrating robotic TCD into national cryptogenic stroke protocols 26:50 – How the Pascal score guides closure decisions 30:00 – Economics: reimbursement and hospital adoption 33:05 – Building trust between neurologists and cardiologists 35:00 – Guidelines and national rollout of robotic TCD 37:05 – Comparing manual vs robotic: why automation wins 42:54 – Structure, incentives, and improving stroke workups 46:47 – Who “owns” the neurovascular lab: neurology vs cardiology 50:16 – Reimbursement and payer considerations 55:38 – Lessons from emerging economies and value-based innovation 58:13 – Future use cases: ambulance, helicopter, and OR monitoring 1:03:34 – Final thoughts and why this is the third chapter of stroke innovationAre you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠⁠⁠⁠⁠GrowMyMedtech.com⁠⁠⁠⁠⁠⁠ to book time for a free analysis.Subscribe to our Youtube Channel⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠⁠⁠⁠⁠Subscribe to our LinkedIn Newsletter⁠⁠⁠⁠⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠⁠⁠⁠⁠Follow The State of MedTech onLinkedIn ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠⁠⁠⁠⁠Instagram ⁠⁠⁠⁠⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠⁠⁠⁠⁠TikTok ⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠⁠⁠⁠⁠X ⁠⁠⁠⁠⁠⁠https://twitter.com/StateofMedTech⁠⁠⁠⁠⁠⁠Facebook ⁠⁠⁠⁠⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠⁠⁠⁠⁠Follow Omar M. Khateeb onLinkedIn ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠⁠⁠⁠⁠Instagram ⁠⁠⁠⁠⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠⁠⁠⁠⁠TikTok ⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠⁠⁠⁠⁠X ⁠⁠⁠⁠⁠⁠https://twitter.com/OmarMKhateeb⁠⁠⁠⁠⁠⁠Facebook ⁠⁠⁠⁠⁠⁠https://www.facebook.com/OmarMKhateeb/⁠⁠⁠This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.#Stroke #Medtech #PFO #Robotics #Diagnostics #HealthcareInnovation